Dave M. Johnson

2.6k total citations · 1 hit paper
15 papers, 745 citations indexed

About

Dave M. Johnson is a scholar working on Organic Chemistry, Molecular Biology and Genetics. According to data from OpenAlex, Dave M. Johnson has authored 15 papers receiving a total of 745 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Organic Chemistry, 5 papers in Molecular Biology and 5 papers in Genetics. Recurrent topics in Dave M. Johnson's work include Chronic Lymphocytic Leukemia Research (5 papers), Synthesis and pharmacology of benzodiazepine derivatives (4 papers) and Lymphoma Diagnosis and Treatment (3 papers). Dave M. Johnson is often cited by papers focused on Chronic Lymphocytic Leukemia Research (5 papers), Synthesis and pharmacology of benzodiazepine derivatives (4 papers) and Lymphoma Diagnosis and Treatment (3 papers). Dave M. Johnson collaborates with scholars based in United States and United Kingdom. Dave M. Johnson's co-authors include Arturo A. Ayón, Gopinath Mani, Devang Patel, Marc D. Feldman, C. Mauli Agrawal, D. Marton, Brian J. Lannutti, Ian W. Flinn, Nina D. Wagner‐Johnston and Thomas M. Jahn and has published in prestigious journals such as Blood, Biomaterials and Langmuir.

In The Last Decade

Dave M. Johnson

15 papers receiving 736 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

2014 465 citations Jennifer R. Brown, John C. Byrd et al. Blood profile →

Peers

Countries citing papers authored by Dave M. Johnson

Since Specialization

Citations

This map shows the geographic impact of Dave M. Johnson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dave M. Johnson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dave M. Johnson more than expected).

Fields of papers citing papers by Dave M. Johnson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dave M. Johnson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dave M. Johnson. The network helps show where Dave M. Johnson may publish in the future.

Co-authorship network of co-authors of Dave M. Johnson

This figure shows the co-authorship network connecting the top 25 collaborators of Dave M. Johnson. A scholar is included among the top collaborators of Dave M. Johnson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dave M. Johnson. Dave M. Johnson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

#	Work	Indexed citations
1	Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia breakdown → 2014 ·Blood ·Jennifer R. Brown, John C. Byrd, Steven Coutré, Don M. Benson, Ian W. Flinn, Nina D. Wagner‐Johnston, Stephen E. Spurgeon, Brad S. Kahl, Celeste Bello, Heather K. Webb, Dave M. Johnson, Sissy Peterman, Daniel Li, Thomas M. Jahn, Brian J. Lannutti, Roger G. Ulrich, Albert S. Yu, Langdon L. Miller, Richard R. Furman	465
2	Phosphoinositide 3'-Kinase (PI3K) Delta Inhibitor, GS-9820, Enhances Anti-Tumor Efficacy When Combined with Conventional Chemotherapeutic Agents in Primary Samples and Human Tumor Xenograft Model of Multiple Myeloma 2012 ·Blood ·Eric Sanchez, Mingjie Li, Cathy Wang, Haiming Chen, Dave M. Johnson, Brian J. Lannutti, James R. Berenson	1
3	Combinations of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kdelta) Inhibitor GS–1101 (CAL-101) with Rituximab and/or Bendamustine Are Tolerable and Highly Active in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL): Results From a Phase I Study 2012 ·Blood ·Steven Coutré, John P. Leonard, Richard R. Furman, Jacqueline C. Barrientos, Sven de Vos, Ian W. Flinn, Marshall T. Schreeder, Nina D. Wagner‐Johnston, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Leanne Holes, Brian J. Lannutti, Dave M. Johnson, Langdon L. Miller, Thomas M. Jahn	30
4	5.43 Patterns of Nodal Response and Lymphocytosis in Patients with Previously Treated CLL Receiving the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, CAL-101 (GS-1101) Alone or in Combination with Rituximab (R) or Bendamustine (B) 2011 ·Clinical Lymphoma Myeloma & Leukemia ·Jennifer R. Brown, Thomas M. Jahn, Richard R. Furman, John P. Leonard, Stephen E. Spurgeon, John C. Byrd, Don M. Benson, Steven Coutré, Nina D. Wagner‐Johnston, Ian W. Flinn, Brad S. Kahl, Marshall T. Schreeder, Sven de Vos, Leanne Holes, (unknown), Dave M. Johnson, Langdon L. Miller	1
5	A Phase 1 Study of the Selective Phosphatidylinositol 3-Kinase-Delta (PI3Kδ) Inhibitor, Cal-101 (GS-1101), in Combination with Rituximab and/or Bendamustine in Patients with Previously Treated, Indolent Non-Hodgkin Lymphoma (iNHL) 2011 ·Blood ·Sven de Vos, Marshall T. Schreeder, Ian W. Flinn, Steven Coutré, John P. Leonard, Nina D. Wagner‐Johnston, Nathan Fowler, Ralph V. Boccia, Jacqueline C. Barrientos, Thomas E. Boyd, Jeff P. Sharman, Leanne Holes, Brian J. Lannutti, Dave M. Johnson, Thomas M. Jahn, Langdon L. Miller	8
6	Work in progress — Military troops to engineers 2010 ·David T. Hayhurst, Dave M. Johnson, (unknown)	1
7	Design, synthesis and polymerization of highly branched pseudodendrimers through tandem reactions 2009 ·Polymer International ·Junyan Wang, Dave M. Johnson	6
8	Drug delivery from gold and titanium surfaces using self-assembled monolayers 2008 ·Biomaterials ·Gopinath Mani, Dave M. Johnson, D. Marton, Marc D. Feldman, Devang Patel, Arturo A. Ayón, C. Mauli Agrawal	88
9	Crystal structure of 2-benzyl-3-(benzylamino)-6-nitroisoindolin-1-one, C22H19N3O3 2008 ·Zeitschrift für Kristallographie - New Crystal Structures ·Junyan Wang, Dave M. Johnson, Edward R. T. Tiekink	2
10	Crystal structure of 2-(3-oxo-1,3-dihydro-2-benzofuran-5-yl)-3-(2- oxopropyl)isoindolin-1-one, C19H15NO4 2008 ·Zeitschrift für Kristallographie - New Crystal Structures ·Junyan Wang, Dave M. Johnson, Edward R. T. Tiekink	2
11	Crystal structure of 2-benzyl-3-hydroxyisoindolin-1-one, C15H13NO2 2008 ·Zeitschrift für Kristallographie - New Crystal Structures ·Junyan Wang, Dave M. Johnson, Edward R. T. Tiekink	1
12	Stability of Self-Assembled Monolayers on Titanium and Gold 2008 ·Langmuir ·Gopinath Mani, Dave M. Johnson, D. Marton, (unknown), Marc D. Feldman, Devang Patel, Arturo A. Ayón, C. Mauli Agrawal	137
13	Characterizing Pseudodendrimers, 1 2007 ·Macromolecular Theory and Simulations ·Dave M. Johnson, Junyan Wang, (unknown)	1
14	6-Amino-3H-isobenzofuran-1-one 2007 ·Acta Crystallographica Section E Structure Reports Online ·Junyan Wang, Dave M. Johnson, Edward R. T. Tiekink	1
15	Crystal structure of 2-[(3-oxo-1,3-dihydro-2-benzofuran-5-yl)methyl]- 1H-isoindole-1,3(2H)-dione, C17H11NO4 2007 ·Zeitschrift für Kristallographie - New Crystal Structures ·Junyan Wang, Dave M. Johnson, G.A. Broker, Edward R. T. Tiekink	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact